-- Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory acceptance for the clinical trial application of GenSci155 injection.
The drug is indicated to prevent bronchopulmonary dysplasia in preterm infants and to treat acute ischemic stroke, according to a Thursday filing with the Shenzhen bourse.